Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 4 clients • 8 examiners • 3 art units • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Double Helix Law is currently managing 5 pending office actions. These applications are situated within the Biotechnology & Pharmaceuticals technology area. The firm's career history includes 164 applications, which provides the context for their current work. The 5 pending office actions represent the current active workload for this firm in the biotech sector.
The firm reports a resolved allowance rate of 44.83 percent. Reaching an allowance typically involves an average of 2.69 office actions. These 5 pending office actions are part of a prosecution practice focused on pharmaceutical technologies. The 44.83 percent allowance rate and 2.69 average office actions per allowance provide a statistical framework for understanding the firm's performance. Practitioners can use the 2.69 average office actions per allowance to estimate the likely progression of these active matters. The 44.83 percent allowance rate serves as a performance metric for the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (25%) |
| §112 only | 4 (50%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONIGLIO, AUDREA JUNE BUCKLEY | 1 | 52.9% | +21.1% |
| MATALKAH, FATIMAH KHALAF | 1 | 54.8% | +28.6% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| JOHNSON, ALLISON MARIE | 1 | 40.9% | +53.3% |
| TINSLEY, BRENDAN THOMAS | 1 | 58.7% | +73.9% |
| BURKHART, MICHAEL D | 1 | 62.3% | +11.7% |
| NICOL, ALEXANDER W | 1 | 42.9% | +43.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 54d |
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | TINSLEY, BRENDAN THOMAS | 134d overdue |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | BURKHART, MICHAEL D | 30d overdue |
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | CONIGLIO, AUDREA JUNE BUCKLEY | — |
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | — |
| 17905649 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTE AGGREGATES | SPENCE, JENNIFER SUZANNE | — |
| 17684405 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTES AND/OR RETROVIRAL PARTICLES | JOHNSON, ALLISON MARIE | — |
| 16478377 | METHODS OF TRANSDUCING AND EXPANDING IMMUNE CELLS AND USES THEREOF | NICOL, ALEXANDER W | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Exuma Biotech | 4 |
| Cellphire | 2 |
| Lifeactive, Inc. | 1 |
| Exuma Biotech Corp. | 1 |
| Art Unit | Apps |
|---|---|
| 1634 | 3 |
| 1638 | 2 |
| 1633 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18942968 | TRANSDERMAL DELIVERY FORMULATIONS AND METHODS FOR THE MANUFACTURE THEREOF | Lifeactive, Inc. | CONIGLIO, AUDREA JUNE BUCKLEY | §103§112 | Non-Final OA | — | Pending | Nov 11, 2024 | |
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | Cellphire, Inc. | MATALKAH, FATIMAH KHALAF | §103 | Non-Final OA | — | Pending | May 02, 2024 | |
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | Cellphire, Inc. | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112Other | Non-Final OA | 54d | Pending | Jun 26, 2023 |
| 17905649 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTE AGGREGATES | Exuma Biotech Corp. | SPENCE, JENNIFER SUZANNE | 1633 | §103 | Non-Final OA | — | Pending | Sep 05, 2022 |
| 17684405 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF MODIFIED LYMPHOCYTES AND/OR RETROVIRAL PARTICLES | Exuma Biotech Corp. | JOHNSON, ALLISON MARIE | 1638 | §112Other | Final Rejection | — | Pending | Mar 01, 2022 |
| 17639281 | METHODS AND COMPOSITIONS FOR THE MODIFICATION AND DELIVERY OF LYMPHOCYTES | Exuma Biotech Corp. | TINSLEY, BRENDAN THOMAS | 1634 | §112 | Non-Final OA | 134d overdue | Pending | Feb 28, 2022 |
| 17272631 | METHODS AND COMPOSITIONS FOR GENETICALLY MODIFYING LYMPHOCYTES IN BLOOD OR IN ENRICHED PBMCS | Exuma Biotech Corp. | BURKHART, MICHAEL D | 1638 | §112 | Final Rejection | 30d overdue | Pending | Mar 01, 2021 |
| 16478377 | METHODS OF TRANSDUCING AND EXPANDING IMMUNE CELLS AND USES THEREOF | Exuma Biotech Corp. | NICOL, ALEXANDER W | 1634 | §112Other | Non-Final OA | — | Pending | Jul 16, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial